Categories: Wire Stories

A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe

TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) and the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan, President: Tasuku Honjo, hereinafter �FBRI’) announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” (HBI* Innovation Program) conducted at the FBRI’s Dept. of Immunology, Institute of Biomedical Research and Innovation (Professor: Akio Ohta). Part of the findings from the above research was published in “Science Immunology**” issued on January 13, 2023 (Eastern Standard Time). For more information, please visit the FBRI website (URL: https://www.fbri-kobe.org/kbic/english/pressrelease/2023_01-16/).

Meiji Seika Pharma and FBRI are working together to develop the above PD-1 agonist monoclonal antibody as therapeutic candidate for autoimmune diseases.

PD-1 is a molecule expressed on activated lymphocytes and has the function as a suppressor of immune responses. Antibodies that inhibit the function of PD-1 (anti-PD-1 blocking antibodies) can enhance anti-tumor immunity, so that they have been applied to cancer treatment as “immune checkpoint inhibitors.”

Through the above joint research supervised by Program Director Tasuku Honjo, Nobel laureate in 2018, Meiji Seika Pharma and FBRI discovered the conditions necessary for inducing immunosuppression by stimulating the function of PD-1 with antibodies. “Anti-PD-1 agonist antibody” is expected to be applied as a novel therapeutic for inflammatory diseases such as autoimmune diseases caused by excessive immune reactions.

Meiji Seika Pharma and FBRI continue to progress the joint research on “anti-PD-1 agonist antibody” and strive to the early contribution of this antibody as a therapeutic agent for autoimmune diseases.

*: HBI: Honjo Kobe Research Center for Biomedical Innovation

**: DOI: 10.1126/sciimmunol.add4947

Contacts

Meiji Seika Pharma Co., Ltd.:
Public Relations, Corporate Development Dept.

Email: pr-pharma (Please add “@meiji.com” to the end)

Foundation for Biomedical Research and Innovation at Kobe:
Public relations and Strategic planning group

Email: kbic-pr (Please add “@fbri-kobe.org” to the end)

Alex

Recent Posts

Michelin Showcases Its Commitment to Innovating for a Sustainable Future at Asia Pacific Media Day 2024 in Thailand

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - Michelin, world-leading manufacturer of…

60 mins ago

Elsie’s Kitchen Unveils Christmas Catering Menus to Elevate Holiday Celebrations

SINGAPORE - Media OutReach Newswire - 22 November 2024 - Elsie's Kitchen is thrilled to…

1 hour ago

PT. Eka Mas Republik (MyRepublic) Celebrates Double Recognition at ACES Awards

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - PT. Eka Mas Republik,…

3 hours ago

Hong Kong’s premier ink art event UOB Art in Ink Festival returns this December, fostering art inclusivity

HONG KONG SAR - Media OutReach Newswire - 21 November 2024 - UOB Art Academy…

14 hours ago

Arbor Partners With Japanese Aomori Prefecture To Unveil A New Japanese-French Culinary Feast

HONG KONG SAR - Media OutReach Newswire - 21 November 202 - Aomori Crafts from…

14 hours ago

Beloved Disney ∙ Pixar Characters Come to Life as 10 FURRY NICE Collectible Furry Friend Sets at 7-Eleven

Collect FunStamps on the New 7-Eleven App and Redeem for FREE HONG KONG SAR -…

14 hours ago